VILNIUS - Novavax's COVID-19 vaccine that was approved for use in the EU in December is expected to reach the bloc's member states in the second half of February, a Lithuanian official said on Tuesday.
"[The vaccine] has been manufactured; it has just arrived in Europe and it is currently undergoing quality assessment and testing," Gytis Andrulionis, director of Lithuania's State Medicines Control Agency, told a news conference.
"It is expected to reach all EU member states around mid-February, on February 19 as planned," he added.
"It is a protein-based, conventional vaccine with a tested production platform, and we will not hide the fact that some people are waiting for this vaccine to get vaccinated," Andrulionis said.
Please enter your username and password.
2025 © The Baltic Times /Cookies Policy Privacy Policy
